ArticleTrials2022
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- Efficacy of scalp cooling to prevent chemotherapy-induced alopecia in children with acute lymphoblastic leukemia: A non-randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Fighting a Dual Battle: The Harrowing Course of B/T Lineage Mixed Phenotype Acute Leukemia in a Child.Indian journal of pediatrics · 2026Article
- The burden of childhood cancers in the South Asian Association for Regional Cooperation (SAARC) Region: a population-based, cross-sectional GLOBOCAN 2022 analysis.The Lancet regional health. Southeast Asia · 2026Article
- Toxicity during induction of pulsed versus continuous prednisolone in children with acute lymphoblastic leukaemia: a multi-centre, open label, randomised, phase 3 trial from India (2016-2022).The Lancet regional health. Southeast Asia · 2026Article
- Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL): Protocol for a Prospective Observational Cohort Study.JMIR research protocols · 2026Article
- Trends in Weight and Triceps Skinfold Thickness During Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia.Indian pediatrics · 2026Article
- Feasibility of an oral hydration regimen post high-dose methotrexate in children with acute leukemia: a pilot study.Discover oncology · 2026Article
- Barriers and facilitators in oral hygiene maintenance in children undergoing chemotherapy for acute lymphoblastic leukemia: a qualitative investigation.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2026Article
- Childhood cancer in India: Progress achieved, persisting gaps, challenges, and the road ahead.The Indian journal of medical research · 2026Article
- Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study.The Lancet regional health. Southeast Asia · 2026Article
- Back pain in an adolescent: not just a sore spine!Ecancermedicalscience · 2026Article
- Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial.EClinicalMedicine · 2025Article
- Landscape of paediatric oncology clinical trials in Asia.EClinicalMedicine · 2025Review
- Genetics of B-Cell Acute Lymphoblastic Leukemia (B-ALL): Recent Updates and Indian Perspective.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Risk stratified treatment for childhood acute lymphoblastic leukaemia: a multicentre observational study from India.The Lancet regional health. Southeast Asia · 2025Article
- Aberrant overexpression of m6A writer and reader genes in pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL).Translational oncology · 2025Article
- Real time-PCR a diagnostic tool for reporting copy number variation and relative gene-expression changes in pediatric B-cell acute lymphoblastic leukemia-a pilot study.Biology methods & protocols · 2025Article
- Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundIn the west, survival following treatment of childhood acute lymphoblastic leukaemia (ALL) approaches 90%. Outcomes in India do not exceed 70%. To address this disparity, the Indian Collaborative Childhood Leukaemia group (ICiCLe) developed in 2013 a contemporary treatment protocol for uniform risk-stratified management of first presentation ALL based on cytogenetics and minimal residual disease levels (MRD). A multicentre randomised clinical trial opened in 2016 (ICiCLe-ALL-14) and examines the benefit of randomised interventions to decrease toxicity and improve outcomes.
methodsPatients 1-18 years with newly diagnosed ALL are categorised into four risk groups based on presentation features, tumour genetics and treatment response. Standard risk includes young (< 10 years) B cell precursor ALL (BCP-ALL) patients with low presentation leucocyte count (< 50 × 10 DISCUSSION: ICiCLe-ALL-14 is the first multicentre randomised childhood cancer clinical trial in India. The pre-trial phase allowed standardisation of risk-stratification diagnostics and established the feasibility of collaborative practice, uniform treatment, patient enrolment and data capture. Pre-trial observations confirm the impact of risk-stratified therapy in reducing treatment-related deaths and costs. Uniform practice across centres allows patients to access care locally, potentially decreasing financial hardship and dislocation.
trial registrationClinical Trials Registry-India (CTRI) CTRI/2015/12/006434 . Registered on 11 December 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.